What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Buy
57
BHC.TO Quote, Financials, Valuation and Earnings
Last price:
$8.74
Seasonality move
:
8.46%
Day range:
$8.41 - $8.59
52-week range:
$5.45 - $13.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.23x
P/B ratio:
--
Volume:
502.7K
Avg. volume:
419.2K
1-year change:
-9.21%
Market cap:
$3.1B
Revenue:
$13.2B
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $6.99, Bausch Health Companies has an estimated downside of -16.64% from its current price of $8.48.
-
Price Target UpsideAccording to analysts, the highest upside price target is $6.99 representing -100% upside increase from its current price of $8.48.
Fair Value
-
According to the consensus of 5 analysts, Bausch Health Companies has -16.64% downside to fair value with a price target of $6.99 per share.
BHC.TO vs. S&P 500
-
Over the past 5 trading days, Bausch Health Companies has overperformed the S&P 500 by 2.71% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bausch Health Companies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bausch Health Companies has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Bausch Health Companies reported revenues of $3.2B.
Earnings Growth
-
Bausch Health Companies earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bausch Health Companies reported earnings per share of -$0.23.
Enterprise value:
33.6B
EV / Invested capital:
1.10x
Price / LTM sales:
0.23x
EV / EBIT:
15.61x
EV / Revenue:
2.49x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
20.11x
Price / Operating cash flow:
1.87x
Enterprise value / EBITDA:
8.63x
Gross Profit (TTM):
$9.6B
Return On Assets:
-0.15%
Net Income Margin (TTM):
-0.42%
Return On Equity:
--
Return On Invested Capital:
-0.19%
Operating Margin:
12.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $10.8B | $12.1B | $13.5B | $2.9B | $3.2B | |
| Gross Profit | $7.6B | $8.6B | $9.6B | $2B | $2.2B | |
| Operating Income | $1.7B | $2.3B | $2.6B | $396.3M | $418.3M | |
| EBITDA | $3.4B | $3.1B | $3.9B | $816.9M | $842.3M | |
| Diluted EPS | -$1.35 | -$1.67 | -$0.15 | -$0.23 | -$0.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.8B | $7.3B | $5.7B | $7.3B | $8.2B | |
| Total Assets | $38.1B | $36.3B | $34.4B | $36.4B | $37.8B | |
| Current Liabilities | $6.2B | $6B | $5.3B | $6B | $6.1B | |
| Total Liabilities | $38.3B | $36.5B | $34.2B | $36.7B | $38.1B | |
| Total Equity | -$156.5M | -$176M | $196.1M | -$235.6M | -$343.4M | |
| Total Debt | $30B | $28.9B | $27.9B | $29.9B | $30.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$657.6M | $1.5B | $2.2B | $284.4M | $302.2M | |
| Cash From Investing | -$428.2M | -$2.9B | -$708.8M | -$98.4M | -$186.2M | |
| Cash From Financing | -$1.4B | $1.7B | -$938M | -$458.3M | -$209.1M | |
| Free Cash Flow | -$1B | $1.1B | $1.7B | $172.6M | $124.6M | |
BHC.TO
Sector
Market Cap
$3.1B
$32.8M
Price % of 52-Week High
61.72%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-9.8%
-35.38%
Beta (5-Year)
0.321
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.24
200-day SMA
Sell
Level
$9.68
Bollinger Bands (100)
Buy
Level
6.6 - 9.88
Chaikin Money Flow
Sell
Level
-32.8M
20-day SMA
Buy
Level
$7.24
Relative Strength Index (RSI14)
Buy
Level
69.43
ADX Line
Buy
Level
36.94
Williams %R
Sell
Level
-10.1871
50-day SMA
Buy
Level
$6.94
MACD (12, 26)
Buy
Level
0.47
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
42.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0341)
Sell
CA Score
(Annual)
Level (-2.5613)
Buy
Beneish M-Score
(Annual)
Level (-2.6347)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.4185)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Stock Forecast FAQ
In the current month, BHC.TO has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BHC.TO average analyst price target in the past 3 months is $6.99.
-
Where Will Bausch Health Companies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bausch Health Companies share price will drop to $6.99 per share over the next 12 months.
-
What Do Analysts Say About Bausch Health Companies?
Analysts are divided on their view about Bausch Health Companies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bausch Health Companies is a Sell and believe this share price will rise from its current level to $6.99.
-
What Is Bausch Health Companies's Price Target?
The price target for Bausch Health Companies over the next 1-year time period is forecast to be $6.99 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BHC.TO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bausch Health Companies is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BHC.TO?
You can purchase shares of Bausch Health Companies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bausch Health Companies shares.
-
What Is The Bausch Health Companies Share Price Today?
Bausch Health Companies was last trading at $8.74 per share. This represents the most recent stock quote for Bausch Health Companies. Yesterday, Bausch Health Companies closed at $8.48 per share.
-
How To Buy Bausch Health Companies Stock Online?
In order to purchase Bausch Health Companies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 42x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
AMBA alert for Jun 25
Ambarella [AMBA] is up 4.36% over the past day.
Buy
65
EXOD alert for Jun 25
Exodus Movement [EXOD] is down 9.63% over the past day.
Buy
78
SMR alert for Jun 25
NuScale Power [SMR] is down 10.59% over the past day.
